UNKNOWNNA

Safety and Efficacy of Immune Therapy for Condyloma

NCT03158480•Shenzhen Second People's Hospital

Summary

Cytokine-induced killer (CIK) cells will be co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to Condylomata Acuminata patients using interferon, whose recurrence rate and total cost will be compared to Condylomata Acuminata patients only use interferon.

Eligibility

Age

20 - 50 years

Sex

ALL

Healthy Volunteers

No

Exclusion Criteria

•\-

Locations (1)

Shenzhen Second Hospital

Shenzhen, Guangdong, China

Key Dates

Start Date

June 25, 2017

Primary Completion Date

December 31, 2018

Completion Date

June 30, 2019

Last Updated

June 29, 2017

Enrollment

80

ESTIMATED participants

Conditions

Condylomata Acuminata

Interventions

DC-CIK immunotherapy

BIOLOGICAL

Carbon Dioxide Laser vs. Electrocoagulation for the Therapy of Condyloma

NCT02520986

Condylomata Acuminata

View study

COMPLETEDPHASE2

Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

NCT03935204

Condylomata AcuminataCervical Cancer

View study

COMPLETEDPHASE3

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 29, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions